AR074083A1 - Uso de antigeno de mycoplasma bovis.composicion inmunogena. metodo - Google Patents

Uso de antigeno de mycoplasma bovis.composicion inmunogena. metodo

Info

Publication number
AR074083A1
AR074083A1 ARP090104219A ARP090104219A AR074083A1 AR 074083 A1 AR074083 A1 AR 074083A1 AR P090104219 A ARP090104219 A AR P090104219A AR P090104219 A ARP090104219 A AR P090104219A AR 074083 A1 AR074083 A1 AR 074083A1
Authority
AR
Argentina
Prior art keywords
bovis
bovine
immunogenic composition
clostridium
pta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ARP090104219A
Other languages
English (en)
Inventor
Phillip Wayne Hayes
Michael Beck
Jeffrey KNITTEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Vetmedica de C V SA
Boehringer Ingelheim Vetmedica Inc
Original Assignee
Boehringer Ingelheim Vetmedica de C V SA
Boehringer Ingelheim Vetmedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica de C V SA, Boehringer Ingelheim Vetmedica Inc filed Critical Boehringer Ingelheim Vetmedica de C V SA
Publication of AR074083A1 publication Critical patent/AR074083A1/es
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/35—Mycoplasma

Abstract

Reivindicacion 1: Una composicion inmunogena para el tratamiento y/o la profilaxis de ganado contra infecciones microbiologicas, caracterizada porque dicha composicion inmunogena comprende: a) uno o más antígenos de M. bovis; y b) uno o más componentes inmunologicamente activos adicionales eficaces para el tratamiento y/o la profilaxis de una infeccion microbiologica en ganado causada por un patogeno de ganado distinto de M. bovis. Reivindicacion 2: La composicion inmunogena de acuerdo con la reivindicacion 1 caracterizada porque el antígeno de M. bovis es una bacteria M. bovis atenuada avirulenta. Reivindicacion 5: La composicion inmunogena de acuerdo con una cualquiera de las reivindicaciones 1 a 4, caracterizada porque la bacteria M. bovis se selecciona del grupo que consiste en: las cepas de bacterias M. bovis atenuadas depositadas con los numeros de acceso de la ATCC PTA-8694, PTA-8695 o PTA-8696; cualquier cepa de bacteria M. bovis descendiente atenuada de las mismas; cualquiera cepa de bacteria M. bovis atenuada avirulenta que tenga las mismas características que cualquiera de las cepas de bacterias M. bovis depositadas con los numeros de acceso de la ATCC PTA-8694, PTA-8695 o PTA-8696 y combinaciones de las mismas. Reivindicacion 7: La composicion inmunogena de acuerdo con una cualquiera de las reivindicaciones 1 a 6, caracterizada porque el componente o componentes inmunologicamente activos adicionales es o son un antígeno o antígenos de uno o más de los patogenos seleccionados del grupo que consiste en: virus de la diarrea Bovina (BVDV), Virus Parainfluenza-3 (PI-3), virus de la Rinotraqueitis Infecciosa Bovina (IBR), Virus Sincitial Respiratorio Bovino (BRSV), Herpesvirus Bovino (BHV), Rotavirus Bovino (BRV), Enterovirus Bovino (BEV), Coronavirus Bovino (BCV), Rabia Bovina (BR), Parvovirus Bovino (BPV), Adenovirus, Astrovirus, Mannheimia haemolytica (antiguamente Pasteurella haemolytica), Pasteurella multocida, Haemophilus somnus (Histophilus ovis y Haemophilus agni). Actinomyces (Corynebacterium), Actinomyces pyogenes, Chlamydia psittaci, Campylobacter fetus venerealis y Campylobacter fetus fetus (antiguamente C. fetus intestinalis), Leptospira interrogans, Leptospira pomona y Leptospira grippotyphosa, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardjo (Leptospira hardjoprajitno y Leptospira hardjo-bovis), Brucella abortus, Brucella suis y Brucella melitensis, Listeria monocytogenes, Chlamydia psittaci, Clostridium chauvoei, Clostridium septicum, Clostridium haemolyticum, Clostridium novyi, Clostridium sordellii, Clostridium perfringens, Clostridium tetani, Moraxella bovis, Klebsiella spp, Klebsiella pneumoniae, Salmonella typhimurium: Salmonella newport, Mycobacterium avium paratuberculosis, Cryptsporidium parvum, Cryptsporidium hominis, Staphylococcus aureus, Streptococcus dysgalactiae, Streptococcus uberis, Streptococcus agalactiae, Escherichia coli, Mycoplasma spp, Mycoplasma dispar y Ureaplasma spp., Tritrichomonas foetus, Trichophyton verrucosum, Trichophyton mentagrophytes, Trichophyton sarkisovii, Neospora caninum (antiguamente Toxoplasma gondii), Babesia bigemina y Babesia bovis, Dictyocaulus viviparous (enfermedad por vermes pulmonares) y combinaciones de los mismos. Reivindicacion 8: La composicion inmunogena de acuerdo con una cualquiera de las reivindicaciones 1 a 7, caracterizada porque la composicion inmunogena es una vacuna de combinacion.
ARP090104219A 2008-10-31 2009-10-30 Uso de antigeno de mycoplasma bovis.composicion inmunogena. metodo Pending AR074083A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11028608P 2008-10-31 2008-10-31

Publications (1)

Publication Number Publication Date
AR074083A1 true AR074083A1 (es) 2010-12-22

Family

ID=41435150

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104219A Pending AR074083A1 (es) 2008-10-31 2009-10-30 Uso de antigeno de mycoplasma bovis.composicion inmunogena. metodo

Country Status (15)

Country Link
US (1) US8815255B2 (es)
EP (1) EP2362780B1 (es)
JP (1) JP2012507537A (es)
KR (1) KR20110089260A (es)
CN (1) CN102202685A (es)
AR (1) AR074083A1 (es)
AU (1) AU2009309041B2 (es)
CA (1) CA2740954C (es)
CL (1) CL2011000877A1 (es)
CO (1) CO6361948A2 (es)
MX (1) MX2011004316A (es)
NZ (1) NZ591950A (es)
SG (1) SG10201506597RA (es)
UY (1) UY32208A (es)
WO (1) WO2010051210A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2121721A4 (en) * 2006-09-07 2010-10-06 Boehringer Ingelheim Vetmed GENOTYPING BASED ON PCR
AR069087A1 (es) * 2007-10-29 2009-12-30 Boehringer Ingelheim Vetmed Cepa bacteriana de m. bovis atenuada avirulenta obtenida por pases, vacuna de micoplasma boris y metodos de uso de la misma
CA2740954C (en) 2008-10-31 2018-09-25 Boehringer Ingelheim Vetmedica, Inc. Multivalent vaccine composition
UY32570A (es) 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada
TR201906323T4 (tr) * 2010-12-22 2019-05-21 Bayer Ip Gmbh Sığır türlerinde artırılmış bağışıklık yanıtı.
US9175049B2 (en) 2012-10-24 2015-11-03 The United States Of America, As Represented By The Secretary Of Agriculture Recombinant mycobacterium avium subsp. paratuberculosis proteins induce immunity and protect against infection
PL2938747T3 (pl) 2012-12-28 2019-11-29 Boehringer Ingelheim Vetmedica Gmbh Sposób wytwarzania szczepionki przeciwko mykoplazmie
AU2015222102B2 (en) 2014-02-28 2021-08-19 Bayer Animal Health Gmbh Immunostimulatory plasmids
BR112018002919B1 (pt) * 2015-08-14 2024-02-27 Zoetis Services Llc Composição imunogênica eficaz compreendendo uma cepa de mycoplasma bovis e usos da mesma para prevenção de doenças causadas por mycoplasma bovis
RU2707289C1 (ru) * 2018-06-07 2019-11-26 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный аграрный университет имени И.Т. Трубилина" Способ изготовления вакцины, ассоциированной против эшерихиоза, стрептококкоза и псевдомоноза крупного рогатого скота
CN111733094B (zh) * 2020-05-29 2022-09-09 内蒙古民族大学 一种牛源蜡样芽孢杆菌及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8296498A (en) 1997-07-10 1999-02-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method of attenuating pathogenic mycobacteria and strains of mycobacteria so attenuated
EP0965639A1 (en) 1998-06-05 1999-12-22 Boehringer Ingelheim Vetmedica Gmbh Attenuated pestiviruses
IL149471A0 (en) 1999-11-08 2002-11-10 Biomune Vaccines for mycoplasma bovis and methods for immunizing bovine amimals
US6548069B2 (en) * 2001-02-03 2003-04-15 Hmv Associates, Inc. Multivalent Mycoplasma bacterin
US20030147914A1 (en) * 2001-07-02 2003-08-07 Pfizer Inc. Mycoplasma bovis vaccine and methods of reducing pneumonia in animals
JP2004537543A (ja) 2001-07-02 2004-12-16 ファイザー・プロダクツ・インク マイコプラズマ・ハイオニューモニエ・ワクチンおよび牛におけるマイコプラズマ・ボビス低減方法
RU2004105962A (ru) 2001-08-28 2005-03-27 Пфайзер Продактс Инк. (Us) Модель инфицирования mycoplasma bovis, способы введения m. bovis и способы индуцирования пневмонических повреждений легких
DE102004025452A1 (de) 2004-05-19 2006-01-19 Boehringer Ingelheim Vetmedica Gmbh Vakzine enthaltend BVDV
US20070009545A1 (en) 2005-07-07 2007-01-11 Joachim Frey Mycoplasma subunit vaccine
EP2121721A4 (en) 2006-09-07 2010-10-06 Boehringer Ingelheim Vetmed GENOTYPING BASED ON PCR
US20090068231A1 (en) 2007-09-11 2009-03-12 Wyeth Live attenuated mycoplasma strains
AR069087A1 (es) 2007-10-29 2009-12-30 Boehringer Ingelheim Vetmed Cepa bacteriana de m. bovis atenuada avirulenta obtenida por pases, vacuna de micoplasma boris y metodos de uso de la misma
CA2729080C (en) 2008-07-03 2018-09-11 Ricardo Rosenbusch Cattle vaccines
CA2740954C (en) 2008-10-31 2018-09-25 Boehringer Ingelheim Vetmedica, Inc. Multivalent vaccine composition
UY32570A (es) 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada

Also Published As

Publication number Publication date
CN102202685A (zh) 2011-09-28
KR20110089260A (ko) 2011-08-05
EP2362780B1 (en) 2019-12-25
SG10201506597RA (en) 2015-10-29
CL2011000877A1 (es) 2011-09-16
US8815255B2 (en) 2014-08-26
AU2009309041A1 (en) 2010-05-06
MX2011004316A (es) 2011-06-16
UY32208A (es) 2010-05-31
US20120093854A1 (en) 2012-04-19
JP2012507537A (ja) 2012-03-29
CA2740954A1 (en) 2010-05-06
WO2010051210A1 (en) 2010-05-06
CO6361948A2 (es) 2012-01-20
EP2362780A1 (en) 2011-09-07
AU2009309041B2 (en) 2016-02-04
CA2740954C (en) 2018-09-25
NZ591950A (en) 2012-12-21

Similar Documents

Publication Publication Date Title
AR074083A1 (es) Uso de antigeno de mycoplasma bovis.composicion inmunogena. metodo
JP2012524548A5 (es)
Vela et al. Antimicrobial susceptibility of clinical strains of Streptococcus suis isolated from pigs in Spain
RU2018117649A (ru) Иммуногенные композиции для иммунизации свиней против цирковируса типа 3 и способы их получения и применения
CO6180452A2 (es) Reduccion de nfecciones concomitantes en cerdos mediante el uso de antigeno pcv2
CA2836805C (en) Bovine vaccines and methods
Aarestrup et al. Trends in the resistance to antimicrobial agents of Streptococcus suis isolates from Denmark and Sweden
RU2008130927A (ru) Поливалентные иммуногенные композиции pcv2 и способы получения таких композиций
Berghaus et al. Plasma pharmacokinetics, pulmonary distribution, and in vitro activity of gamithromycin in foals
AR039545A1 (es) Vacuna de bacterina de mycoplasma hyopneumoniae mejorada
Pieters et al. An experimental model to evaluate Mycoplasma hyopneumoniae transmission from asymptomatic carriers to unvaccinated and vaccinated sentinel pigs
Takeuti et al. Detection of Mycoplasma hyopneumoniae in naturally infected gilts over time
Michiels et al. Efficacy of one dose vaccination against experimental infection with two Mycoplasma hyopneumoniae strains
BR112019009399A2 (pt) atenuação da virulência bacteriana por atenuação do transporte de folato bacteriano
Naz et al. Isolation, characterization and monitoring of antibiotic resistance in Pasteurella multocida isolates from buffalo (Bubalus bubalis) herds around Lahore.
Shouval et al. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines
Sacristán et al. Efficacy of florfenicol injection in the treatment of Mycoplasma hyopneumoniae induced respiratory disease in pigs
Post Overview of bacteria
Morshed et al. Drug resistance, plasmid profile and random amplified polymorphic DNA analysis of Iranian isolates of Salmonella enteritidis.
D’Amours et al. Genetic diversity and tetracycline resistance genes of Histophilus somni
Siwińska et al. The unique structure of bacterial polysaccharides-Immunochemical studies on the O-antigen of Proteus penneri 4034-85 clinical strain classified into a new O83 Proteus serogroup
Borrelli et al. Salmonella typhimurium DT104 in farmed rabbits
KR20120054037A (ko) 돼지 흉막폐렴에 대하여 유도된 백신 및 그러한 백신의 수득 방법
May et al. Secreted sialidase activity of canine mycoplasmas
Ramirez Diseases affecting pigs: An overview of common bacterial, viral and parasitic pathogens of pigs

Legal Events

Date Code Title Description
FB Suspension of granting procedure